Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy

Liver International

Volumn 25, Issue 1, 2005, Pages 85-90

  Moriyama, Mitsuhiko ^a   Matsumura, Hiroshi ^a   Aoki, Hiroshi ^a   Shimizu, Toshihiro ^a   Yamagami, Hiroaki ^a   Shioda, Atsuo ^a   Kaneko, Miki ^a   Goto, Iori ^a   Tanaka, Naohide ^a   Arakawa, Yasuyuki ^a  

^a NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

ALT above upper limit of normal; Interferon; Non responder; Sustained biochemical response; Sustained virologic response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; VIRUS RNA;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BIOCHEMISTRY; CANCER RISK; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PREDICTION; PROGNOSIS; RELAPSE; RISK FACTOR; TREATMENT OUTCOME; VIROLOGY;

ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; REFERENCE VALUES; RISK; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 20044376484     PISSN: 14783223     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2005.01028.x     Document Type: Article

References (15)

1. Hoofnagle J H, Mullen K D, Jones B, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 1986; 615: 1575-8.
2. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174-81.
3. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factor for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 1998; 27: 1394-402.
4. Toyoda H, Kumada T, Nakano S, et al. The effect of treatment with interferon-alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C. Cancer 2000; 88: 58-65.
5. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomized trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051-5.
6. Tanaka K, Sata M, Uchiyama Y, Tanikawa K. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma? Oncol Rep 1998; 5: 205-8.
7. Miyajima I, Sata M, Kumashiro R, Uchiyama Y, Ide T, Suzuki H, Tanikawa K. The incidence of hepatocellular carcinoma in patients with chronic hepatitis C after interferon treatment. Oncol Rep 1998; 5: 201-4.
8. Tarao K, Rino Y, Ohkawa S, et al. Association between high serum alanine aminotransferase levels and more rapid development and higher rate of incidence of hepatocellular carcinoma in patients with hepatitis C virus-associated cirrhosis. Cancer 1999; 86: 589-95.
9. Matsumura H, Moriyama M, Tanaka N, Arakawa Y. Therapeutic effect of interferon on patients with type C chronic active hepatitis: comparison between complete responders and non-responders. Nihon Univ J Med 1997; 39: 267-76.
10. Kasahara A, Hayashi N, Mochizuki K, et al. Clinical characteristics of patients with chronic hepatitis c showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. J Viral Hepatol 2000; 7: 343-51.
11. Matsumura H, Moriyama M, Tanaka N, Okubo H, Uchida T, Arakawa Y. The serum hepatitis C virus RNA at two weeks after the administration of interferon: Its predictability for the efficacy of interferon treatment for chronic hepatitis C. Nihon Univ J Med 1998; 40: 61-9.
12. Matsumura H, Moriyama M, Goto I, Tanaka N, Ohkubo H, Arakawa Y. Natural course of progression of liver fibrosis in patients with chronic liver disease type C in Japan - a study of 527 patients at one establishment in Japan. J Viral Hepatol 2000; 7: 268-75.
13. Okamoto H, Sugiyama Y, Okada S, et al. Typing of hepatitis C virus by PCR with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol 1992; 73: 673-9.
14. Simmonds P, Alberti A, Alter HJ, et al. A proposed system for the of hepatitis C viral genotypes. Hepatology 1994; 19: 1321-4.
15. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994; 19: 1513-20.